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The purpose of this paper was to determine the eﬃcacy and safety of topical tacrolimus, compared to cyclosporine, for treating
keratoconjunctivitis sicca (KCS) in dogs. This study was a two-phase, randomized, controlled, masked clinical trial. Phase 1
evaluated ophthalmic 0.03% tacrolimus in normal dogs. Ocular examinations were performed daily. Phase 2 evaluated the eﬃcacy
of tacrolimus in treating KCS. Half the dogs received 2% cyclosporine A; the others received 0.03% tacrolimus, both diluted in
olive oil. Four ophthalmic examinations were done over 12 weeks. There was no signiﬁcant diﬀerence between groups in phase
I. In phase 2, there was no signiﬁcant diﬀerence in Schirmer tear test I (STT) results between the two groups, and both groups
had a signiﬁcant increase in STT over time. Both drugs were eﬀective in increasing the STT in dogs na¨ ıve to lacrimostimulants.
Tacrolimus was eﬀective in increasing the STT in 4 dogs currently nonresponsive to cyclosporine.
1.Introduction
Keratoconjunctivitis sicca (KCS) is a deﬁciency of the
aqueous layer of the precorneal tear ﬁlm. Clinical signs
in dogs with KCS include mucopurulent ocular discharge,
conjunctivitis, keratitis, and blepharospasm. Dogs with KCS
have a Schirmer tear test I (STT) result of <10mm/minute,
and severely aﬀected dogs often have an STT result of
0mm/min. While many causes of KCS in dogs have been
described [1–10] ,K C Si nd o g si sm o s to f t e nc o n s i d e r e d
to be immune-mediated based on studies that showed
increased numbers of lymphocytes and plasma cells with
acinar atrophy in the lacrimal glands [11, 12]. Immune-
mediated KCS is typically bilateral and aﬀects many breeds.
Treatmentofimmune-mediatedKCSisaimedatdecreas-
ing the immune response in the lacrimal gland and restoring
aqueous tear production. Cyclosporine A (CsA) is a com-
monly used and eﬀective treatment for canine KCS [13–
16].Formulationstypicallyusedarepreviouslycommercially
available as 0.2% CsA ophthalmic ointment (Optimmune),
and 1% and 2% CsA in olive or corn oil [13–19]. In
addition to increasing tear production by inhibiting T-helper
lymphocyte proliferation and inﬁltration of lacrimal gland
acini,CsArestoresconjunctivalgobletcellmucinproduction
[12, 13, 17, 18]. Previous studies have shown that dogs
treated with ophthalmic CsA treatment have a decreased
lymphocyte stimulation index compared to control dogs and
that there are measurable levels of CsA in peripheral blood
of treated dogs [20, 21]. However, a more recent study did
not show a change in the lymphocyte stimulation index or
signiﬁcant blood levels with use of topical cyclosporine [22].
Unfortunately, approximately 25% of dogs with KCS do not
respond to treatment with 1% or 2% CsA [15–17].
Tacrolimus is a newer immunosuppressant agent that
has been used for the treatment of immune-mediated KCS
in dogs [23]. Tacrolimus is a macrolide antibiotic that has
a similar immunopharmacological proﬁle as CsA but is
approximately 100-times more potent than CsA [24–26].
In 2005, the United Stated Federal Drug Administration
issued an advisory for the potential carcinogenic eﬀects of2 Veterinary Medicine International
the dermal tacrolimus when used on humans. This advisory
recommended that tacrolimus only be used as a second-
line agent for short-term and intermittent use [27]. This
advisory was based on a small number of patients, and the
ramiﬁcations for dogs being treated with tacrolimus for KCS
are not known.
Both CsA and tacrolimus are calcineurin inhibitors that
reversibly inhibit T-cell proliferation and prevent the release
of proinﬂammatory cytokines. Calcineurin inhibitors bind
to intracellular immunophilins and form complexes that
subsequently bind to and inhibit calcineurin. In blocking
calcineurin, translocation of the cytoplasmic component of
the nuclear factor of activated T cells to the nucleus is
prevented. This prevention of translocation impairs tran-
scription of the genes encoding IL-2 and other cytokines,
thereby suppressing T-cell proliferation and normal immune
function [28].
Theﬁrstpurposeofthisstudywastodeterminethesafety
of topical tacrolimus in normal dogs. The second purpose
wastocomparetheeﬃcacyoftopicalophthalmicapplication
of 0.03% tacrolimus with that of 2% CsA in olive oil in a
double-masked study.
2.MaterialsandMethods
This study was designed as a two-phase, controlled, masked,
randomized clinical trial. Phase 1 was a toxicity study, and
phase 2 was an eﬃcacy study. This study was approved
by the University of Tennessee Animal Care and Use
Committee. Thirteen clinically normal research beagles were
treated in the toxicity study. Prior to inclusion in the
study, all dogs received complete ophthalmic examinations
including STT, ﬂuorescein staining, tonometry, slit-lamp
biomicroscopy, and indirect ophthalmoscopy. Each dog
was randomly assigned to either the tacrolimus or control
group. Seven dogs were treated twice daily topically with
the injectable form of tacrolimus (5mg/mL; Fujisawa Inc.,
Japan) formulated into a 0.03% concentration in an olive
oil vehicle. Six dogs were treated twice daily with the olive
oil vehicle alone. All dogs were treated for 14 days. All
dogs received daily ophthalmic examinations including STT,
ﬂuorescein staining, and slit lamp biomicroscopy during
the treatment period. Daily clinical scores were assigned to
each dog grading the severity of conjunctival hyperemia,
blepharospasm, and epiphora by a masked observer (EA).
The grading scale consisted of grades 0 through 3 for each of
the criteria evaluated. Grade 0 was considered normal, grade
1m i l d l ya ﬀected, grade 2 moderately aﬀected, and grade 3
severelyaﬀected.Serumbiochemistryproﬁleswereevaluated
on days 0 and 15 to determine if the treatment caused any
alterations in these values.
For the phase 2 eﬃcacy study, patients were enrolled
for 12 weeks. Inclusion criteria consisted of an STT result
less than 10mm/minute in both eyes (OU) even with
current CsA treatment, clinical signs of KCS OU, and written
consent of the owner. Exclusion criteria included corneal
ulceration, suspected bacterial keratitis, systemic neoplasia,
immunosuppressive therapy for a systemic disease, and
previous treatment with sulfonamides or etodolac.
Dogs were randomly assigned to 1 of 2 groups. One
group was treated with 2% CsA in olive oil OU BID, and
the other group was treated with 0.03% tacrolimus in olive
oil OU BID. Any medications that the patient was currently
receiving to treat KCS such as antibiotic ointment and ocular
lubricants were continued during the course of the study.
Five dogs in the CsA group were already being treated with
CsA (three with 2% solution and two with 0.2% ointment).
Six dogs in the tacrolimus group were already being treated
with CsA (four with 2% solution and two with 0.2%
ointment). Upon enrollment, the current CsA formulation
was discontinued and the CsA or tacrolimus treatment was
initiated without having a washout period. Criteria used
to terminate participation in the study included corneal
ulceration, development of bacterial keratitis, or signs of
excessive ocular irritation secondary to drug administration.
Eachdogwasevaluatedonday0andatweeks4,8,and12
ofthestudybyamaskedobserver(EA,DH,DW,orBS).Each
dog had a complete ophthalmic examination at each evalu-
ation, including STT, ﬂuorescein staining, slit lamp biomi-
croscopy, and indirect ophthalmoscopy. Serum biochemistry
proﬁles were evaluated at weeks 0 and 4 of the study.
Both eyes of each dog in the study were photographed at
each visit and were graded by a masked observer (DH). Clin-
ical signs were evaluated as follows: conjunctival hyperemia
(score 0: no conjunctival hyperemia, 1: mild hyperemia, 2:
moderate hyperemia), ocular discharge (score 0: no ocular
discharge, 1: slight ocular discharge at medial canthus, 2:
dischargeacrosscorneaoroneyelidmargins),areaofcorneal
pigmentation (score 0: no corneal pigmentation, 1: pigment
over less than 25% of the cornea, 2: pigment over 25–50% of
thecornea,3:pigmentover50–75%ofthecornea,4:pigment
over >75% of the cornea), corneal pigment density (score
0: no pigment, 1: iris easily visualized through the pigment,
2: iris partially visualized through the pigment, 3: iris not
visible through the pigment), corneal vessel length (Score
0-no corneal vessels, 1: limbal corneal vessels, 2: vessels
halfway towards the corneal axis, 3: vessels extending to axial
cornea), corneal vessel density (Score 0: no vessels, 1: vessels
extending to cornea from <25% of the circumference of the
limbus, 2: vessels extending to cornea from 25–50% of the
circumference of the limbus, 3: vessels extending to cornea
from 50–75% of the circumference of the limbus, 4: vessels
extending to cornea from >75% of the circumference of the
limbus), and corneal keratinization (score 0: none, 1: mild
opacity, 2: moderate opacity).
Data from both eyes from each dog were combined
for statistical analysis. For phase 1, the daily clinical scores
and STT results between the two groups were compared by
Student’s t-test. Within each group the eﬀect of treatment on
STT over time was evaluated by repeated measures analysis
of variance (RM-ANOVA).
For the clinical study, the data from both eyes from each
dog was combined. Within each group the eﬀect of the treat-
ments on STT and clinical scores over time was evaluated by
one-way RM-ANOVA. When normality failed, the Freidman
repeated measures ANOVA on ranks was used. The STT and
clinical scores comparing the CsA and tacrolimus groups on
day 0, and at weeks 4, 8, and 12 were evaluated by Student’sVeterinary Medicine International 3
t-test. Statistical signiﬁcance was set at P ≤ .05. Statistical
analyses were done with SPSS software (SPSS Inc., Chicago,
Illinois).
3. Results
For all dogs in phase 1, the serum biochemistries were within
referencerangesonday0andday15.Therewasnodiﬀerence
between the two groups in the daily clinical scores (data not
shown). Mean STT on day 0 was 19.08 (±2.7) for the control
group and 20.64 (±3.2) in the tacrolimus group. On day
15, the mean STT was 21.08 (±2.3) for the control group
and 24.29 (±3.2) for the tacrolimus group. There was no
statistical diﬀerence in clinical scores between groups on day
0o rd a y1 5o rb e t w e e nS T To nd a y0a n dd a y1 5o v e rt i m ei n
either group.
Of the 29 dogs enrolled in the eﬃcacy study, 18 dogs
completed the study, with 10 dogs in the CsA group and
eight dogs in the tacrolimus group. Of the 18 dogs, 16 were
pure breeds, representing 14 diﬀerent breeds, and two were
mixed-breed dogs. Nine were spayed females, one was an
intact female, four were neutered males, and four were intact
males. Mean age in the CsA group was 8 years, and mean
age in the tacrolimus group was 9 years. Five dogs in the CsA
group and six dogs in the tacrolimus group had been treated
with CsA prior to enrolling in the study.
Six dogs in the CsA group and eight dogs in the
tacrolimus group had photographic images from all visits
available for scoring. There was no signiﬁcant diﬀerence in
combined clinical scores for conjunctival hyperemia, ocular
discharge, corneal pigmentation, corneal vascularization, or
keratinization over time for the CsA or tacrolimus groups.
There was no statistical diﬀerence in clinical scores between
theCsAgroupandtacrolimusgroupatday0,week4,orweek
8. There was a signiﬁcant diﬀerence in the clinical scores
between the CsA group and the tacrolimus group at week
12 (P = .040). The CsA group had lower clinical scores than
the tacrolimus group at all time points, although this was not
signiﬁcant except at week 12.
Both groups had an increase in mean tear production
over time. In both groups, the STT was higher at the
fourth visit (CsA group: median 11mm/minute, range 1.5–
21.5; tacrolimus group: median 9.75mm/min, range 7–
20mm/minute) compared to the ﬁrst visit (CsA group:
median 5mm/minute, range 0–8.5mm/minute; tacrolimus
group: median 4.5mm/minute, range 0–6.5). This diﬀerence
between the STT at time 0 and at week 12 in both groups was
signiﬁcant (CsA, P<. 001, tacrolimus P = .001; Table 1).
There was no signiﬁcant diﬀerence in mean STT between
the groups at time 0, 4 weeks, 8 weeks, or 12 weeks (Table 2).
No dogs had any signs of irritation from either drug.
Serum biochemistry values were within normal limits for all
patients.
Four of ﬁve dogs in the CsA group not previously treated
with lacrimostimulants responded with an increase in tear
production >5mm/minute when treated with CsA. There
was no change in the tear production in the one dog that
did not respond. Of the ﬁve dogs in the CsA group that
were already being treated with CsA (three with 2% solution
Table 1: Median tear production (STT) inmm/min at baseline and
week 12 for the cyclosporine group and the tacrolimus group.
Group Baseline (range) 12 weeks (range) P value
Cyclosporine 5 (0–8.5) 11 (1.5–21.5) P<. 001
Tacrolimus 4.5 (0–6.5) 9.75 (7–20) P = .001
Table 2: Mean tear production (STT) inmm/min at baseline, 4
weeks, 8 weeks, and 12 weeks for the cyclosporine group and the
tacrolimus group. There was no diﬀerence between groups at any
time.
Time (weeks) Cyclosporine Tacrolimus P value
Baseline 4.6 3.2 P = .336
49 . 3 7 . 0 P = .302
8 10.8 10.0 P = .768
12 11.7 11.1 P = .850
and two with 0.2% ointment), only one dog, which was
being treated with 2% CsA prior to being enrolled in the
study, had an increase in STT of >5mm/minute. Only two
dogs in the tacrolimus group were not already being treated
with CSA at time of enrollment in the study, and they both
responded with a tear production increase >5mm/minute.
Fourofthesixdogsinthetacrolimusgroupthatwerealready
being treated with CsA (two with 2% CsA in oil and two
with 0.2% CsA ointment) had an increase in mean STT
>5mm/minute. Two dogs did not have a mean increase in
STT >5mm/minute. One of those had a tear production
of 5mm/minute in the right eye with no change during
the study and the left eye increased from 8mm/minute in
to 12mm/minute at 12 weeks. The other dog was similar
and had no change in the right eye, but the STT increased
from 0mm/minute in the left eye upon enrollment to
9mm/minute at 12 weeks.
4. Discussion
The results of this small, short-term study support
tacrolimus ophthalmic solution as potentially successful
in increasing tear production in dogs nonresponsive to
treatment with CsA. As previously reported, both CsA and
tacrolimus are useful in the treatment of dogs with KCS
previously not treated with lacrimostimulants [13–16, 23].
A previous study investigating the eﬀects of 2% CsA
in olive oil administered TID in normal beagles showed
a signiﬁcant increase in STT after 7 days. Our study did
not show a signiﬁcant increase in tear production between
the dogs treated with 0.03% tacrolimus in olive oil and
control dogs treated with the olive oil alone after 14 days
of BID treatment. However, a direct comparison between
the two studies cannot be made because of the diﬀerence in
treatment frequency.
While the numbers are small, having a response of
>5mm/minute STT in the majority of dogs na¨ ıve to CsA was
expected, as was having most of the dogs that were already4 Veterinary Medicine International
being treated with CsA not show a response. The single
dog in the CsA group that was already being treated with
2% CsA that responded to the study CsA with an increase
in STT >5mm/minute may have done so simply because
of increased owner compliance. Of the eight dogs in the
tacrolimus group, two that were na¨ ıve to lacrimostimulant
therapy and four that were already being treated with CsA
(two with 2% CsA in oil and two with 0.2% CsA ointment)
responded to the tacrolimus. While the numbers are small in
this study (using tacrolimus as a 0.03% solution in olive oil),
these results support the ﬁndings by Berdoulay who used
0.02% aqueous solution that tacrolimus may be eﬀective at
increasing tear production in dogs nonresponsive to CsA
[23].
Signiﬁcant improvement in clinical signs over time was
n o ts e e ni nt h i ss t u d y .T h i si si nc o n t r a s tt op r e v i o u s
studies evaluating CsA and tacrolimus that found a decrease
in severity of signs both with and without increased tear
production [17, 23]. In contrast to those studies, which
evaluated only ocular discharge and signs of conjunctivitis,
thecurrentstudyalsoassessedcornealpigmentation,corneal
vascularization, and corneal keratinization. These signs
develop with chronicity and are also expected to require
more time to improve. The clinical signs of the dogs of this
study may have improved signiﬁcantly with a longer follow-
up period.
This study used olive oil rather than a lactose cellulose
basefortheincreasedlubricationandcontacttimeassociated
with an oil base. Similar eﬃcacy of the tacrolimus in olive oil
compared to the aqueous base was seen, and there were no
complications seen with the olive oil base [23]. Therefore,
it may be the formulation of choice in dogs with very low
tear production or in dogs with increased corneal exposure
secondary to lagophthalmos.
CsAwasusedasthecontrolinthisstudytoensurethatno
eyes deteriorated due to lack of standard and proven trea-
tment of KCS. To assure that diﬀerences between the two
drugs could not be attributed to diﬀerent vehicles, both the
CsA and tacrolimus were diluted in olive oil. Unfortunately
for this study, most dogs in our region are treated appropri-
ately for KCS, and, therefore, we were not able to obtain large
numbersofdogsthathadnothadCsAtherapyinitiatedprior
to the study.
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